Profile picture of Muhammad Ali

Dr Muhammad Ali

Radiation Oncologist
Become a Patient

Dr Muhammad Ali is dedicated to delivering comprehensive, patient-centred care, ensuring his patients and their loved ones are supported throughout treatment and beyond.


Dr Muhammad Ali is a radiation oncologist at Icon Cancer Centre Warrnambool. He completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at Nishtar Medical College in 2006 and undertook specialist clinical oncology training at Pakistan’s Shaukat Khanum Memorial Cancer Hospital and Research Centre. Dr Ali subsequently worked as an associate radiation oncology consultant at Prince Sultan Military Medical City between 2013-2018, gaining extensive experience in managing a broad range of cancers. In 2021, he became a fellow of the Royal Australian and New Zealand College of Radiologists (RANZCR) after completing training in Victoria.

Dr Ali maintains a strong interest in clinical research, quality assurance and medical education. He enjoys providing emerging medical professionals with support and mentorship required to provide high level patient care for radiation therapy patients. His clinical experience covers a broad range of malignancies with a special interest in breast cancer, head and neck cancer, lung cancer, skin cancer and urological cancers.

Affiliations & Memberships

  • European Society of Medical Oncology (ESMO)
  • Pakistan Society of Clinical Oncology (PSCO)
  • Radiation Oncology Society of Pakistan (ROSP)
  • Royal Australian and New Zealand College of Radiologists (RANZCR)

Special Interests

Dr Muhammad Ali accepts referrals for all cancer types, with a special clinical interest in:
  • Breast cancer
  • Head and neck cancer
  • Lung cancer
  • Prostate cancer
  • Skin cancer

Icon Locations

Warrnambool View centre


  • Synchronous p16+ Nasopharyngeal and Oropharyngeal Squamous Cell Carcinoma: A Case Report and review. M. Ali, H. Kua, C. Giddings, D. Day & L. McDowell. Clinical Case Reports, 2021; 9: 1350-1353.

  • Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review. J. Ansari, M. Ali, A. Farrag. A.M. Ali & A. Alhamad. Case Reports in Immunology, 2018.

  • Atypical diffuse bilateral cystic lung changes secondary to erlotinib treatment in a patient with metastatic non-small cell lung carcinoma: A case report and literature review. J. Ansari, E. Batubara, M. Ali, A. Farrag, F. Bashir, H. Farghaly, A.M. Ali & A. Shaukat. Molecular and Clinical Oncology, 2018; 9(1): 92-95.

  • Intracranial meningioma as primary presentation for an undiagnosed collision metastatic breast cancer: Case report and literature review. A. Farrag, J. Ansari, M. Ali, G. Sunbuli, H. Kassem & A.A. Hamad. Molecular and Clinical Oncology, 2018; 8(5): 661-664.

  • Pretreatment Neutrophil-To-Lymphocyte Ratio (NLR) as a Prognostic Factor of Outcome for Patients with Oral Cavity Squamous Cell Carcinoma: A Single Institution Experience. A. Farrag, A. Shaukat, M. Ali & M. Kandil. International Journal of Cancer and Clinical Research, 2018; 5(3): 100.

View all